Post-FDA Evidence Needed To Inform Coverage Decisions – McClellan
This article was originally published in The Gray Sheet
Executive Summary
Generating comparative effectiveness data is most realistic after FDA approval, but improved mechanisms are needed, according to CMS Administrator Mark McClellan
You may also be interested in...
CMS Coverage Of Post-Approval Studies Seeks To Improve Data For NCDs
CMS' decision to pay for carotid artery stenting with embolic protection in post-approval studies advances the agency's interest in efficiently gathering data to better inform national coverage determinations
CMS Coverage Of Post-Approval Studies Seeks To Improve Data For NCDs
CMS' decision to pay for carotid artery stenting with embolic protection in post-approval studies advances the agency's interest in efficiently gathering data to better inform national coverage determinations
McClellan Discusses Research Alternatives To Comparative Clinical Trials
CMS Administrator Mark McClellan plans to promote healthcare information technology in an effort to decrease the number of comparative clinical studies needed to answer health outcomes-related questions